RNAi Therapeutics Market Global Industry Analysis and Forecasts to 2030: A $20.23 Billion Market in 2030, with a CAGR of a 7.69% During 2023-2030
January 17, 2024 12:03 ET
|
Research and Markets
Dublin, Jan. 17, 2024 (GLOBE NEWSWIRE) -- The "RNAi Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030" report has been added to ResearchAndMarkets.com's...
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
January 08, 2024 08:00 ET
|
Wave Life Sciences USA, Inc.
Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans Selection of...
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
December 07, 2023 08:00 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
November 17, 2023 08:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023 16:30 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
November 09, 2023 07:30 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
November 03, 2023 12:00 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 12, 2023 11:00 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
October 11, 2023 07:30 ET
|
Phio Pharmaceuticals Corp.
--Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination --Preclinical data demonstrates the effectiveness of...
RNAi Drug Delivery Technologies and Global Market Analysis Report 2023: Historic Market Revenue from 2020 to 2022, Estimates for 2023, and CAGR Projections through to 2028
August 29, 2023 07:08 ET
|
Research and Markets
Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "RNAi Drug Delivery: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global RNAi drug delivery...